Last reviewed · How we verify
Cital
At a glance
| Generic name | Cital |
|---|---|
| Also known as | Paramol |
| Sponsor | Ain Shams University |
| Target | Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Depressive disorder
- Generalized anxiety disorder
- Major depressive disorder
Common side effects
- Ejaculation disorder
- Nausea
- Insomnia
- Dizziness
- Somnolence
- Asthenia
- Dry mouth
- Vomiting
- Agitation
Serious adverse events
- Suicidal thoughts and behaviors
- QT-prolongation and torsade de pointes
- Serotonin syndrome
- Increased risk of bleeding
- Activation of mania or hypomania
- Seizures
- Angle-closure glaucoma
- Hyponatremia
- Discontinuation syndrome
- Hypersensitivity reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |